Hemogenyx Pharmaceuticals (LON:HEMO) Stock Price Up 14.2%

Hemogenyx Pharmaceuticals Plc (LON:HEMO) shares traded up 14.2% during trading on Thursday . The stock traded as high as GBX 1.60 ($0.02) and last traded at GBX 1.54 ($0.02). 12,736,362 shares were traded during mid-day trading, an increase of 49% from the average session volume of 8,574,797 shares. The stock had previously closed at GBX 1.35 ($0.02).

Hemogenyx Pharmaceuticals Stock Up 12.7 %

The stock has a fifty day simple moving average of GBX 1.30 and a two-hundred day simple moving average of GBX 1.51. The firm has a market cap of £20.33 million, a PE ratio of -144.80 and a beta of 3.21. The company has a current ratio of 3.33, a quick ratio of 6.72 and a debt-to-equity ratio of 105.93.

Hemogenyx Pharmaceuticals Company Profile

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.